Telisotuzumab adizutecan
M25-279
Phase 2 small_molecule active
Quick answer
Telisotuzumab adizutecan for Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active